Literature DB >> 1685185

Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

S M Efange1, R J Boudreau.   

Abstract

Nineteen analogs of the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have been used as probes to study the structural parameters that influence MAO-catalyzed oxidation. In this study, the efficiency of enzyme-catalyzed substrate oxidation was found to be unrelated to parameters such as the ionization potential, dipole moment, net atomic charge at C5 and the dihedral angle between the phenyl ring and the tetrahydropyridine moiety. Conformational analysis revealed that substitution at the C2' position of MPTP yields atropisomers. It is suggested that one of these atropisomers would be either inactive or substantially less active than the other. Therefore, the relative oxidative efficiency and toxicity of these compounds reported earlier may have been significantly underestimated. Based on the conformational analysis and other data, a rudimentary model of the MAO substrate site has been developed which partially explains the substrate specificities of MAO A and MAO B. Each substrate binding site can be divided into two regions, (a) an amine-binding pocket (for the tetrahydropyridine moiety), and (b) a 'bulky substituent' region (for the phenyl group and its substituents). The length of the substrate binding site (measured along the long axis of MPTP) is approximately 8.5 A, and the width of the 'amine-binding' pocket is approximately 2.5 A (from C3 to C5). The 'bulky substituent' region contains a central area for binding the phenyl group of MPTP. This central area is flanked by two hydrophobic pockets, P2' and P3'. In MAO A, the pocket P2'-A is oriented 45-135 degrees relative to the plane of the tetrahydropyridine moiety, with a radius of 3.1 A from C2' of the phenyl ring. The radius of a similar but smaller pocket, P2'-B, in MAO B, is approximately 2.7 A. In MAO B, the pocket P3'-B (radius 2.36 A from C3') is larger than a similar pocket P3'-A (radius 1.70 A from C3') in MAO A. The foregoing characterization suggests that differences in the size and topography of both of the substituent pockets play an important role in determining the substrate specificities of these two isozymes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685185     DOI: 10.1007/bf00125661

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  33 in total

1.  Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. II. Evaluation of the biological activity of the pyridinium metabolites formed from the monoamine oxidase-catalyzed oxidation of MPTP analogs.

Authors:  S K Youngster; W J Nicklas; R E Heikkila
Journal:  J Pharmacol Exp Ther       Date:  1989-06       Impact factor: 4.030

Review 2.  MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture.

Authors:  S H Snyder; R J D'Amato
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

3.  Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  T P Singer; N Castagnoli; R R Ramsay; A J Trevor
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

4.  Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects.

Authors:  J N Johannessen; C C Chiueh; R S Burns; S P Markey
Journal:  Life Sci       Date:  1985-01-21       Impact factor: 5.037

Review 5.  MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology.

Authors:  W Schultz
Journal:  Gen Pharmacol       Date:  1988

6.  Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.

Authors:  G C Davis; A C Williams; S P Markey; M H Ebert; E D Caine; C M Reichert; I J Kopin
Journal:  Psychiatry Res       Date:  1979-12       Impact factor: 3.222

7.  Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  R E Heikkila; M V Kindt; P K Sonsalla; A Giovanni; S K Youngster; K A McKeown; T P Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 8.  Processing of MPTP by monoamine oxidases: implications for molecular toxicology.

Authors:  A J Trevor; T P Singer; R R Ramsay; N Castagnoli
Journal:  J Neural Transm Suppl       Date:  1987

9.  1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-CH3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice.

Authors:  S K Youngster; R C Duvoisin; A Hess; P K Sonsalla; M V Kindt; R E Heikkila
Journal:  Eur J Pharmacol       Date:  1986-03-18       Impact factor: 4.432

10.  Potent neurotoxic fluorinated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs as potential probes in models of Parkinson disease.

Authors:  N J Riachi; P K Arora; L M Sayre; S I Harik
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

View more
  1 in total

Review 1.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.